Results 91 to 100 of about 305,738 (309)

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Somatic tumor mutations detected by targeted next generation sequencing in minute amounts of serum-derived cell-free DNA [PDF]

, 2017
The use of blood-circulating cell-free DNA (cfDNA) as 'liquid-biopsy' is explored worldwide, with hopes for its potential in providing prognostic or predictive information in cancer treatment.
Beaufort, C.M. (Corine M.), Dinjens, W.N.M. (Winand), Helmijr, J. (Jean), Jansen, M.P.H.M. (Maurice), Krol, N.M.G. (Niels M. G.), Marion, R. (Ronald) van, Martens, J.W.M. (John), Sleijfer, S. (Stefan), Trapman-Jansen, A.M.A.C. (Anita M.A.C.), Weerts, M.J.A. (Marjolein)   +9 more
core   +4 more sources

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

Molecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena, Karin Teien Lande, Eva Diaz, Ana Vilar, Juan Cueva, Efigenia Arias, Victoria Sampayo, Alicia Abalo, Nerea González, Eva Colás, Antonio Gil‐Moreno, Miguel Abal, Gema Moreno‐Bueno, Therese Sørlie, Kristina Lindemann, Laura Muinelo‐Romay   +15 more
wiley   +1 more source

Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma

Biomolecules
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults, characterized by rapid growth and resistance to chemotherapy. Conventional treatments remain largely ineffective, with patient survival averaging around 18 months after diagnosis ...
Bruna Pereira de Lima, Leticia Silva Ferraz, Sylvie Devalle, Helena Lobo Borges   +3 more
doaj   +1 more source

Circulating tumor DNA in early‐stage breast cancer: personalized biomarkers for occult metastatic disease and risk of relapse?

EMBO Molecular Medicine, 2015
The availability of blood‐based markers to predict response of a solid tumor to treatment, estimate patient prognosis and diagnose relapse well before clinical symptoms arise, is a long‐standing hope in clinical oncology.
Taija M af Hällström, Maija Puhka, Olli Kallioniemi   +2 more
doaj   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Biopsy confirmation of metastatic sites in breast cancer patients:clinical impact and future perspectives [PDF]

, 2014
Determination of hormone receptor (estrogen receptor and progesterone receptor) and human epidermal growth factor receptor 2 status in the primary tumor is clinically relevant to define breast cancer subtypes, clinical outcome,and the choice of therapy ...
A Santinelli, AJ Montero, Alastair M Thompson, AM Thompson, Angela Esposito, Aron Goldhirsch, B Weigelt, BG Mobbs, C Liedtke, C Simmons, C Tapia, CA Gomez-Roca, Carmen Criscitiello, CH Lu, D Gancberg, DS Seah, E Amir, E Amir, E Brogi, EA Mittendorf, EA Perez, EA Perez, EE Lower, EE Lower, F Andre, F André, F Liebens, Fabrice André, Franco Orsi, G Aurilio, G Bogina, G Curigliano, G Viale, Giuseppe Curigliano, HJ Chang, Ida Minchella, J Carlsson, JM Wu, L Ding, L Pusztai, LD Hoefnagel, LM Bender, LS Lindstrom, LS Steelman, Luca Fumagalli, Lucia Gelao, M Scaltriti, Marzia Locatelli, Michele De Laurentiis, MJ Higgins, N Niikura, PJ Stephens, PK Idirisinghe, R Fisher, R Simon, RJ Broom, RJ Leary, S Gupta, S Vignot, SJ Aitken, SM Edgerton, SP Shah, ST Wong, T Forshew, U Wilking, V Guarneri, W Onstenk, Y Gong, Y Nagata, YM Lo   +69 more
core   +5 more sources

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Screening and epitope characterization of Nidogen‐2‐specific nanobodies

FEBS Open Bio, EarlyView.
Camel immunization and phage display were employed to generate high‐affinity VHH nanobodies against Nidogen‐2. After library construction, biopanning, ELISA screening, sequencing, and recombinant expression, selected nanobodies were purified and characterized, leading to the preliminary exploration of a nanobody‐based sandwich ELISA for specific ...
Jianchuan Wen, Qianqian Cui, Zhongyun Lan, Yingjun Wang, Shuaiying Zhao, Wenxuan Feng, Yunfeng Liu, Qiting Huang, Dongna Zhang, Jianfeng Xu   +9 more
wiley   +1 more source